About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com [http://www.lilly.com/] and newsroom.lilly.com/social-channels [http://newsroom.lilly.com/social-channels]. P-LLY
This press release contains certain forward-looking statements about solanezumab, an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there is no guarantee that future study results and patient experience will be consistent with study findings to date or that solanezumab will receive regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
(1) Liu-Seifert H., et al. Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia. Journal of Alzheimer's Disease. 43 (2015) 949-955 (2) Alzheimer's Society. The Mini Mental State Examination. https://www.alzheimers.org.uk/site/scrip... [https://www.alzheimers.org.uk/site/scrip...]. Accessed November 2016 (3) The Washington University Knight ADRC. http://alzheimer.wustl.edu/CDR/CDR.htm [http://alzheimer.wustl.edu/CDR/CDR.htm]. Accessed November 2016. (4) Liu-Seifert H., et al. Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia. Journal of Alzheimer's Disease. 43 (2015) 949-955 (5) Alzheimer's Association. Tools for Early Identification, Assessment, and Treatment for People with Alzheimer's Disease and Dementia. https://www.alz.org/national/documents/b... [https://www.alz.org/national/documents/b...]. Accessed November 2016. (6) Alzheimer's Association. 2016 Alzheimer's Disease Facts and Figures. http://www.alz.org/documents_custom/2016-facts-and-figures.p... [http://www.alz.org/documents_custom/2016-facts-and-figures.p...]. Accessed November 2016. (7) Alzheimer's Disease International. Dementia statistics. http://www.alz.co.uk/research/statistics... [http://www.alz.co.uk/research/statistics...]. Accessed November 2016.
Refer to: Media - Nicole Hebert; hebert_nicole@lilly.com; 317.701.9984 Investors - Phil Johnson; johnson_philip_l@lilly.com; 317.655.6874
http://photos.prnewswire.com/prnvar/2003... [http://photos.prnewswire.com/prnvar/2003...]
Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]
Web site: http://www.lilly.com/
